MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Merck & Co. DPO Ratio 2011-2026 | MRK
Annual DPO Ratio Merck & Co.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 94.5 | 96.1 | 92.6 | 93 | 123 | 112 | 96.7 | 89.6 | 88.6 | 73.8 | 61.9 | 57.1 | 49 | 38.9 | 53.3 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 123 | 38.9 | 81.3 |
Quarterly DPO Ratio Merck & Co.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 95.1 | 98.5 | 98.3 | 79.5 | 85.7 | 90.5 | 74.4 | 80.8 | 92.3 | - | 39.1 | 40.2 | 70.6 | - | 96 | 117 | 119 | - | 131 | 148 | 115 | - | 85.5 | 100 | 105 | - | 83.7 | 88.6 | 92 | - | 85.6 | 90.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 148 | 39.1 | 92.4 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Coherus BioSciences
CHRS
|
507 | $ 1.57 | -3.68 % | $ 184 M |  USA |
 |
Happiness Biotech Group Limited
HAPP
|
5.06 K | - | 1.35 % | $ 17.8 M |  China |
 |
Amphastar Pharmaceuticals
AMPH
|
31.7 | $ 16.87 | -2.49 % | $ 789 M | USA |
 |
AgeX Therapeutics
AGE
|
5.24 K | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
AstraZeneca PLC
AZN
|
265 | - | - | $ 96.9 B |  Britain |
 |
Eton Pharmaceuticals
ETON
|
74.3 | $ 30.26 | 1.0 % | $ 814 M | USA |
 |
Exelixis
EXEL
|
148 | $ 50.13 | -1.9 % | $ 13.6 B | USA |
 |
Fortress Biotech
FBIO
|
400 | $ 2.41 | 4.78 % | $ 67.2 M | USA |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M | Britain |
 |
Autolus Therapeutics plc
AUTL
|
9.57 | $ 1.63 | 2.52 % | $ 434 M | Britain |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Celyad Oncology SA
CYAD
|
55.8 K | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
135 | - | -7.31 % | $ 87 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M |  Israel |
 |
Gilead Sciences
GILD
|
45.3 | $ 129.58 | -1.88 % | $ 161 B | USA |
 |
Advaxis
ADXS
|
85.6 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M |  Canada |
 |
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
193 | $ 0.72 | -1.58 % | $ 32.9 M | Israel |
 |
Esperion Therapeutics
ESPR
|
7.93 K | $ 3.12 | - | $ 649 M | USA |
 |
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | USA |